Search Follow us

vectura

1 - 12 of 43
Sort by: popularity | newest
Page  2 3 4  of 4 | Next
Skyepharma

Vectura and Skyepharma announce merger

Flash note | Pharmaceutical & healthcare | 17 Mar 2016

Vectura and Skyepharma (SKP) have announced they have reached a merger agreement; under the terms of the deal SKP shareholders will be entitled to receive 2.7977 new Vectura shares for every SKP share, valuing the company at £441.3m or 410.15p per share. Our last published valuation (A shining start to 2016) of SKP is 422p/share. The rationale for the merger is to combine the complementary inhalation businesses and create an industry-leading respiratory speciality business to accelerate growth in the global inhaled market and provide shareholders of the enlarged company with a broader product and development portfolio. Based on the closing share price on 15 March, the newly enlarged group would have had a pro-forma market capitalisation of £1,014.3m.

Vectura

Daily comment

Institutional Comment | Pharmaceutical & healthcare | 30 Jun 2014

-

Greggs

Daily comment

Institutional Comment | Food & Drink | 30 Jun 2014

-

Petrofac

Daily comment

Institutional Comment | Engineering | 24 Jun 2014

-

Chemring

Daily comment

Institutional Comment | Aerospace & Defence | 24 Jun 2014

-

Vectura

Daily comment

Institutional Comment | Pharmaceutical & healthcare | 24 Jun 2014

-

Xaar

Daily comment

Institutional Comment | Electronics & Electrical Equipment | 24 Jun 2014

-

Ryanair

Daily comment

Institutional Comment | Travel & Leisure | 24 Jun 2014

-

Vectura

Getting a second wind

QuickView | Pharmaceutical & healthcare | 31 Mar 2014

Vectura's €130m acquisition of private German smart nebuliser technology company Activaero has addressed its pipeline gap in a single deal, adding seven clinical programmes based on the FAVORITE inhalation platform. These should effect a second wave of regulatory filings for branded respiratory products from 2017 onwards. As outlined at its recent investor day, Vectura now has a broader and more balanced pipeline, underpinned by formulation and device technologies, with which to build a sustainable business focused on treating airways diseases. Upcoming catalysts for H114 remain US filings of NVA237 and QVA149, and top-line VR506 data.

Vectura

Breathe a sigh of relief

QuickView | Pharmaceutical & healthcare | 20 Dec 2013

Vectura's partner Sandoz has received its first European approval in Denmark for AirFluSal, a generic version of GSK's Seretide for asthma/chronic obstructive pulmonary disease (COPD). AirFluSal, formerly VR315, is delivered via Vectura's proprietary Gyrohaler inhaler. It is the third Vectura-developed respiratory product to receive European approval following those of the two Novartis-partnered COPD drugs, Seebri Breezhaler (in 2012) and Ultibro Breezhaler (earlier in 2013). Royalties on product sales will strengthen an already solid cash balance of £65.5m.

Futura Medical

Edison healthcare quarterly: Immuno-oncology 2: The combos come

Sector Commentary: | Pharmaceutical & healthcare | 06 Nov 2013

-

Trillium Therapeutics

Edison healthcare quarterly: Immunotherapy takes centre stage

Sector Commentary: | Pharmaceutical & healthcare | 31 Jul 2013

-